Clinical trial
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects…
NCT00299871 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00299871 |
|---|---|
| Title | Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus |
| Official title | A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | LIXISENATIDE (AVE0010) |
| Enrollment | 542 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Mar 7, 2006 |
| Last update posted | Jan 28, 2014 |
| Countries | Brazil, Canada, Poland, Romania, Russia, Ukraine, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: